Completed PHASE1 INTERVENTIONAL 1-arm NCT01709435

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Primary Central Nervous System Neoplasm Recurrent Thyroid Gland Carcinoma Refractory Malignant Solid Neoplasm Refractory Primary Central Nervous System Neoplasm Thyroid Gland Medullary Carcinoma

Interventions Cabozantinib S-malate Laboratory Biomarker Analysis Pharmacological Study

Updated 26 times since 2017 Last updated: Dec 21, 2023 Started: Nov 14, 2012 Primary completion: Dec 31, 2018 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01709435, this PHASE1 trial focuses on Recurrent Malignant Solid Neoplasm and Recurrent Melanoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 26 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

26 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Oct 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE1

Status: Completed → Active Not Recruiting

▶ Show 21 earlier versions

Jan 2021 — Oct 2023 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Apr 2020 — May 2020 [monthly]

Active Not Recruiting PHASE1
Feb 2020 — Apr 2020 [monthly]

Active Not Recruiting PHASE1
Dec 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE1
Sep 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE1
Aug 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE1
Jul 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE1
Jun 2019 — Jul 2019 [monthly]

Active Not Recruiting PHASE1
Apr 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE1
Mar 2019 — Apr 2019 [monthly]

Active Not Recruiting PHASE1
Feb 2019 — Mar 2019 [monthly]

Active Not Recruiting PHASE1
Dec 2018 — Feb 2019 [monthly]

Active Not Recruiting PHASE1
Nov 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE1
Jun 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE1
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Jul 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE1
Jun 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE1
Apr 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Bethesda, United States , Birmingham, United States , Chicago, United States , Cincinnati, United States , Houston, United States , Indianapolis, United States , Memphis, United States , Milwaukee, United States and 11 more locations